Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Arcutis Biotherapeutics, Inc. ARQT NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
62/100
4/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$33.33
+32.8%

Arcutis Biotherapeutics, Inc. (ARQT) is a Biotechnology company in the Healthcare sector, currently trading at $25.09. It has a SharesGrow Score of 62/100, indicating a above average investment profile with 4 out of 7 criteria passed.

Analyst consensus target is ARQT = $33 (+32.8% upside).

Valuation: ARQT trades at a trailing Price-to-Earnings (P/E) of -192.7 (S&P 500 average ~25).

Financials: revenue is $376M, +612.7%/yr average growth. Net income is $16M (loss), growing at +50.3%/yr. Net profit margin is -4.3% (negative). Gross margin is 90.2% (+10.7 pp trend).

Balance sheet: total debt is $6M against $189M equity (Debt-to-Equity (D/E) ratio 0.03, conservative). Current ratio is 3.17 (strong liquidity). Debt-to-assets is 1.4%. Total assets: $433M.

Analyst outlook: 10 / 12 analysts rate ARQT as buy (83%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 90/100 (Pass), Growth 100/100 (Pass), Past 0/100 (Fail), Health 67/100 (Partial), Moat 70/100 (Pass), Future 94/100 (Pass), Income 10/100 (Fail).

$33.33
▲ 32.84% Upside
Average Price Target
Based on 12 Wall Street analysts offering 12-month price targets for Arcutis Biotherapeutics, Inc., the average price target is $33.33, with a high forecast of $37.00, and a low forecast of $29.00.
Highest Price Target
$37.00
Average Price Target
$33.33
Lowest Price Target
$29.00

ARQT SharesGrow Score Overview

72/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 90/100
Valuation — P/E, PEG, Forward PEG
GROWTH 100/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 70/100
Gross margin is + market cap
FUTURE 94/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — ARQT

✓
VALUE Pass
90/100
ARQT trades at a trailing Price-to-Earnings (P/E) of -192.7 (S&P 500 average ~25). Forward PEG -0.75 — Peter Lynch undervalued (≤1.0). Analyst consensus target is $33, implying +31.5% from the current price $25. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✓
GROWTH Pass
100/100
ARQT: +612.7%/yr revenue is, +50.3%/yr Net income is average growth. > 5%/yr — strong. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
67/100
Balance sheet ARQT: Debt-to-Equity (D/E) ratio 0.03 (conservative), Current ratio is 3.17 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✓
MOAT Pass
70/100
ARQT: Gross margin is 90.2% (+10.7 pp trend), $3B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 70/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
94/100
Analyst outlook: 10 / 12 analysts rate ARQT as buy (83%). Analyst consensus target is $33 (+31.5% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
ARQT: Net profit margin is -4.3%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range11.86-31.77
Volume1.58M
Avg Volume (30D)1.32M
Market Cap$3.11B
Beta (1Y)1.77
Share Statistics
EPS (TTM)-0.13
Shares Outstanding$127.23M
IPO Date2020-01-31
Employees342
CEOTodd Franklin Watanabe
Financial Highlights & Ratios
Revenue (TTM)$376.07M
Gross Profit$339.38M
EBITDA$2.48M
Net Income$-16.14M
Operating Income$-12.23M
Total Cash$220.98M
Total Debt$6.27M
Net Debt$-36.64M
Total Assets$432.97M
Price / Earnings (P/E)-193
Price / Sales (P/S)8.27
Analyst Forecast
1Y Price Target$34.00
Target High$37.00
Target Low$29.00
Upside+35.5%
Rating ConsensusBuy
Analysts Covering12
Buy 83% Hold 17% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS03969K1088

Price Chart

Track all markets on TradingView
ARQT
Arcutis Biotherapeutics, Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
11.86 52WK RANGE 31.77

People Also View

ERAS
ERAS
Erasca, Inc.
$17.85
+9.44%
 APLS
APLS
Apellis Pharmaceuticals, Inc.
$40.85
+0.02%
 MIRM
MIRM
Mirum Pharmaceuticals, Inc.
$96.90
+0.42%
 TERN
TERN
Terns Pharmaceuticals, Inc.
$52.68
+0.13%
 MRTX
MRTX
Mirati Therapeutics, Inc.
$58.70
-0.17%
 DAWN
DAWN
Day One Biopharmaceuticals, Inc.
$21.46
-0.14%
 AMLX
AMLX
Amylyx Pharmaceuticals, Inc.
$16.92
+2.73%
 GLUE
GLUE
Monte Rosa Therapeutics, Inc.
$17.50
-0.28%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message